John M. McLaughlin, PhD

Sr. Director, Clinical Epidemiology
Pfizer

Disclosure(s): Pfizer: Employee, Stocks/Bonds (Public Company)

Dr. McLaughlin is Vice President and Global Medical Lead for Antifectives and COVID-19, Influenza, and mRNA vaccines at Pfizer.

Poster(s):

• (P-1906) Early COVID-19 and Severity of Subsequent Omicron Infection in Ontario, Canada.
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT

• (P-2048) COVID-19 XBB.1.5 Vaccine Uptake Based on State Vaccine Registries Compared to National Survey Data
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT

• (P-2054) Effectiveness of a Single COVID-19 mRNA Vaccine Dose in Individuals Previously Infected with SARS-CoV-2: A Systematic Review
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT

• (P-2062) COVID-19 XBB.1.5-adapted Vaccine Uptake in Immunocompromised Individuals Using Tokenized State Vaccine Registries
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT